{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:35:46Z","timestamp":1791527746447,"version":"4.3.4"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.rmed.2023.107217","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T22:29:55Z","timestamp":1678919395000},"page":"107217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Towards development of evidence to inform recommendations for the evaluation and management of bronchiectasis"],"prefix":"10.1016","volume":"211","author":[{"given":"Patrick A.","family":"Flume","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Basavaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Di Mango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3324-926X","authenticated-orcid":false,"given":"Charles L.","family":"Daley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie V.","family":"Philley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Henkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1968-1400","authenticated-orcid":false,"given":"Mark","family":"Metersky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2023.107217_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.rmed.2019.04.007","article-title":"Incidence of patients with non-cystic fibrosis bronchiectasis in Germany - a healthcare insurance claims data analysis","volume":"151","author":"Diel","year":"2019","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2023.107217_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study","volume":"47","author":"Quint","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2023.107217_bib3","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1378\/chest.11-2209","article-title":"Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007","volume":"142","author":"Seitz","year":"2012","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.rmed.2023.107217_bib4","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.chest.2018.07.014","article-title":"Characteristics and health-care utilization history of patients with bronchiectasis in US Medicare enrollees with prescription drug plans, 2006 to 2014","volume":"154","author":"Henkle","year":"2018","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.rmed.2023.107217_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1479972317709649","article-title":"Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013","volume":"14","author":"Weycker","year":"2017","journal-title":"Chron. Respir. Dis."},{"key":"10.1016\/j.rmed.2023.107217_bib6","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity","volume":"392","author":"Flume","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.rmed.2023.107217_bib7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study","volume":"47","author":"Quint","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2023.107217_bib8","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.rmed.2023.107217_bib9","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1164\/rccm.201002-0157OC","article-title":"Clinical practice guidelines for pulmonary therapies committee, cystic fibrosis foundation pulmonary therapies committee, cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax","volume":"182","author":"Flume","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.rmed.2023.107217_bib10","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Clinical practice guidelines for pulmonary therapies committee, cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2023.107217_bib11","first-page":"522","article-title":"Clinical practice guidelines for pulmonary therapies committee, cystic fibrosis pulmonary guidelines: airway clearance therapies","volume":"54","author":"Flume","year":"2009","journal-title":"Respir. Care"},{"issue":"7","key":"10.1016\/j.rmed.2023.107217_bib12","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Pulmonary Clinical Practice Guidelines Committee, Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10","key":"10.1016\/j.rmed.2023.107217_bib13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","article-title":"Cystic Fibrosis Foundation, Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"176","author":"Flume","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"Suppl 1","key":"10.1016\/j.rmed.2023.107217_bib14","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US cystic fibrosis foundation, European cystic fibrosis society, US cystic fibrosis foundation and European cystic fibrosis society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"issue":"Suppl 1","key":"10.1016\/j.rmed.2023.107217_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212463","article-title":"British thoracic society guideline for bronchiectasis in adults","volume":"74","author":"Hill","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2023.107217_bib16","series-title":"Chronic Suppurative Lung Disease and Bronchiectasis in Children and Adults in Australia and New Zealand","year":"2014"},{"issue":"3","key":"10.1016\/j.rmed.2023.107217_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2023.107217_bib18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/17476348.2021.1882853","article-title":"Personalized approaches to bronchiectasis","volume":"15","author":"Gir\u00f3n Moreno","year":"2021","journal-title":"Expet Rev. Respir. Med."},{"issue":"3","key":"10.1016\/j.rmed.2023.107217_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01269-2018","article-title":"Treatable traits in bronchiectasis","volume":"52","author":"Boaventura","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"12","key":"10.1016\/j.rmed.2023.107217_bib20","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1513\/AnnalsATS.201507-472OC","article-title":"Etiology of non\u2013cystic fibrosis bronchiectasis in adults and its correlation to disease severity","volume":"12","author":"Lonni","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.rmed.2023.107217_bib21","first-page":"6","article-title":"Inflammation: a two-edged sword--the model of bronchiectasis","volume":"147","author":"Cole","year":"1986","journal-title":"Eur. J. Respir. Dis. Suppl."},{"issue":"8","key":"10.1016\/j.rmed.2023.107217_bib22","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/resp.12832","article-title":"Aetiology of bronchiectasis in adults: a systematic literature review","volume":"21","author":"Gao","year":"2016","journal-title":"Respirology"},{"issue":"Suppl 64","key":"10.1016\/j.rmed.2023.107217_bib23","first-page":"PA2170","article-title":"Inflammatory molecular endotypes in bronchiectasis","volume":"54","author":"Shoemark","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2023.107217_bib24","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.chest.2016.10.055","article-title":"Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry","volume":"151","author":"Aksamit","year":"2017","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.rmed.2023.107217_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/20734735.0119-2021","article-title":"Precision medicine in bronchiectasis","volume":"17","author":"Pembridge","year":"2021","journal-title":"Breathe"},{"issue":"5","key":"10.1016\/j.rmed.2023.107217_bib26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1590\/S1806-37132010000500005","article-title":"Adhesiveness and purulence of respiratory secretions: implications for mucociliary transport in patients with bronchiectasis","volume":"36","author":"Tambascio","year":"2010","journal-title":"J. Bras. Pneumol."},{"issue":"11","key":"10.1016\/j.rmed.2023.107217_bib27","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","article-title":"Characterization of the \u201cfrequent exacerbator phenotype\u201d in bronchiectasis","volume":"197","author":"Chalmers","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"Suppl 1","key":"10.1016\/j.rmed.2023.107217_bib28","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1080\/15412555.2017.1286171","article-title":"Bronchiectasis: phenotyping a complex disease","volume":"14","author":"Chalmers","year":"2017","journal-title":"COPD"},{"issue":"4","key":"10.1016\/j.rmed.2023.107217_bib29","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1183\/13993003.01899-2015","article-title":"Clinical phenotypes in adult patients with bronchiectasis","volume":"47","author":"Aliberti","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.rmed.2023.107217_bib30","first-page":"1602","article-title":"A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis","volume":"12","author":"Finch","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"11","key":"10.1016\/j.rmed.2023.107217_bib31","doi-asserted-by":"crossref","first-page":"e1000","DOI":"10.1016\/j.ijid.2013.03.018","article-title":"Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis","volume":"17","author":"Mirsaeidi","year":"2013","journal-title":"Int. J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.rmed.2023.107217_bib32","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00844-2021","article-title":"Artificial intelligence in computed tomography for quantifying lung changes in the era of CFTR modulators","volume":"59","author":"Dournes","year":"2022","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.rmed.2023.107217_bib33","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1007\/s00330-017-4819-7","article-title":"Diagnosis of bronchiectasis and airway wall thickening in children with cystic fibrosis: objective airway-artery quantification","volume":"27","author":"Kuo","year":"2017","journal-title":"Eur. Radiol."},{"issue":"5","key":"10.1016\/j.rmed.2023.107217_bib34","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s00330-019-06606-w","article-title":"Normal Chest CT study group, Airway tapering: an objective image biomarker for bronchiectasis","volume":"30","author":"Kuo","year":"2020","journal-title":"Eur. Radiol."},{"issue":"2","key":"10.1016\/j.rmed.2023.107217_bib35","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2023.107217_bib36","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/cei.13595","article-title":"Bronchiectasis is associated with delayed diagnosis and adverse outcomes in the New Zealand Common Variable Immunodeficiency Disorders cohort study","volume":"204","author":"Ameratunga","year":"2021","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2023.107217_bib37","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1479972317702139","article-title":"Sex bias in diagnostic delay in bronchiectasis: an analysis of the Spanish Historical Registry of Bronchiectasis","volume":"14","author":"Gir\u00f3n","year":"2017","journal-title":"Chron. Respir. Dis."},{"issue":"6","key":"10.1016\/j.rmed.2023.107217_bib38","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.rmed.2006.11.008","article-title":"Aetiology in adult patients with bronchiectasis","volume":"101","author":"Shoemark","year":"2007","journal-title":"Respir. Med."},{"issue":"24","key":"10.1016\/j.rmed.2023.107217_bib39","doi-asserted-by":"crossref","first-page":"E828","DOI":"10.1503\/cmaj.160830","article-title":"Diagnosis and management of bronchiectasis","volume":"189","author":"Smith","year":"2017","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"issue":"12","key":"10.1016\/j.rmed.2023.107217_bib40","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1164\/rccm.201805-0819ST","article-title":"American thoracic society assembly on pediatrics, diagnosis of primary ciliary dyskinesia, an official American thoracic society clinical practice guideline","volume":"197","author":"Shapiro","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.rmed.2023.107217_bib41","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.chest.2017.07.037","article-title":"Bronchiectasis management: the state of the union","volume":"152","author":"Chalmers","year":"2017","journal-title":"Chest"},{"issue":"2015","key":"10.1016\/j.rmed.2023.107217_bib42","first-page":"CD008351","article-title":"Airway clearance techniques for bronchiectasis","volume":"11","author":"Lee","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.rmed.2023.107217_bib43","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1378\/chest.113.5.1329","article-title":"Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group","volume":"113","author":"O'Donnell","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2023.107217_bib44","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.rmed.2018.06.031","article-title":"A qualitative synthesis of gastro-oesophageal reflux in bronchiectasis: current understanding and future risk","volume":"141","author":"McDonnell","year":"2018","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2023.107217_bib45","series-title":"Clinical Guideline [CG184]. Gastro-Oesophageal Reflux Disease and Dyspepsia in Adults: Investigation and Management","year":"2014"},{"issue":"1","key":"10.1016\/j.rmed.2023.107217_bib46","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41533-017-0019-9","article-title":"Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults","volume":"27","author":"Chalmers","year":"2017","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.rmed.2023.107217_bib47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fmed.2020.00123","article-title":"Serum biomarkers for inflammatory bowel disease","volume":"7","author":"Chen","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.rmed.2023.107217_bib48","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.2147\/COPD.S311236","article-title":"Inhaled corticosteroid therapy in bronchiectasis is associated with all-cause mortality: a prospective cohort study","volume":"16","author":"H\u00e5kansson","year":"2021","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"12","key":"10.1016\/j.rmed.2023.107217_bib49","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S2213-2600(16)30320-4","article-title":"Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study","volume":"4","author":"McDonnell","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2023.107217_bib50","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01264-2018","article-title":"Pulmonary rehabilitation in bronchiectasis: a propensity-matched study","volume":"53","author":"Patel","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.rmed.2023.107217_bib51","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00051-2017","article-title":"EMBARC\/BRR definitions working group, Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research","volume":"49","author":"Hill","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2023.107217_bib52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12890-019-0818-6","article-title":"The economic burden of bronchiectasis - known and unknown: a systematic review","volume":"19","author":"Goeminne","year":"2019","journal-title":"BMC Pulm. Med."},{"issue":"5","key":"10.1016\/j.rmed.2023.107217_bib53","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jcf.2018.12.004","article-title":"Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis","volume":"18","author":"Flume","year":"2019","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.rmed.2023.107217_bib54","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12931-015-0167-9","article-title":"Lung function, symptoms and inflammation during exacerbations of non-cystic fibrosis bronchiectasis: a prospective observational cohort study","volume":"16","author":"Brill","year":"2015","journal-title":"Respir. Res."},{"issue":"5","key":"10.1016\/j.rmed.2023.107217_bib55","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","article-title":"The bronchiectasis severity index. An international derivation and validation study","volume":"189","author":"Chalmers","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2023.107217_bib56","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0035-1546752","article-title":"The microbiome and emerging pathogens in cystic fibrosis and non-cystic fibrosis bronchiectasis","volume":"36","author":"Green","year":"2015","journal-title":"Semin. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2023.107217_bib57","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jcf.2019.01.008","article-title":"Antimicrobial Resistance in Cystic Fibrosis International Working Group, Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: a systematic review","volume":"18","author":"Somayaji","year":"2019","journal-title":"J. Cyst. Fibros."},{"issue":"9","key":"10.1016\/j.rmed.2023.107217_bib58","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S2213-2600(19)30254-1","article-title":"Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial","volume":"7","author":"Goyal","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"6","key":"10.1016\/j.rmed.2023.107217_bib59","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04388-2020","article-title":"Feasibility of shortening intravenous antibiotic therapy for bronchiectasis based on bacterial load: a proof-of-concept randomised controlled trial","volume":"58","author":"Bedi","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.rmed.2023.107217_bib60","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1164\/rccm.202102-0461OC","article-title":"STOP2 Investigators, A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment","volume":"204","author":"Goss","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.rmed.2023.107217_bib61","first-page":"CD012406","article-title":"Macrolide antibiotics for bronchiectasis","volume":"3","author":"Kelly","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"17","key":"10.1016\/j.rmed.2023.107217_bib62","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015285","article-title":"Meta-analysis of macrolide maintenance therapy for prevention of disease exacerbations in patients with noncystic fibrosis bronchiectasis","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.rmed.2023.107217_bib63","first-page":"CD013198","article-title":"Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis","volume":"1","author":"Janjua","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.rmed.2023.107217_bib64","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.rmed.2013.09.014","article-title":"Nontuberculous mycobacterial (NTM) lung disease: the top ten essentials","volume":"108","author":"Aksamit","year":"2014","journal-title":"Respir. Med."},{"issue":"3","key":"10.1016\/j.rmed.2023.107217_bib65","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.regg.2014.09.005","article-title":"Inhaled colistin in elderly patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa bronchial infection [in Spanish]","volume":"50","author":"Tabernero Huguet","year":"2015","journal-title":"Rev. Esp. Geriatr. Gerontol."},{"issue":"9","key":"10.1016\/j.rmed.2023.107217_bib66","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2023.107217_bib67","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02052-2017","article-title":"RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"De Soyza","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2023.107217_bib68","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"9","key":"10.1016\/j.rmed.2023.107217_bib69","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"ORBIT-2 investigators, Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.rmed.2023.107217_bib70","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"8","key":"10.1016\/j.rmed.2023.107217_bib71","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201312-2208OC","article-title":"Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection","volume":"189","author":"Haworth","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2023.107217_bib72","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis","volume":"183","author":"Murray","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2023.107217_bib73","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00608-2020","article-title":"Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a post hoc analysis of the AIR-BX studies","volume":"56","author":"Crichton","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"12","key":"10.1016\/j.rmed.2023.107217_bib74","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.cmi.2019.04.017","article-title":"Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection","volume":"25","author":"VanDevanter","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"issue":"7","key":"10.1016\/j.rmed.2023.107217_bib75","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1164\/rccm.201507-1449LE","article-title":"Aerosolized antibiotics for patients with bronchiectasis","volume":"193","author":"Nadig","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2023.107217_bib76","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1183\/23120541.00786-2020","article-title":"Comparative safety of inhaled corticosteroids and macrolides in Medicare enrolees with bronchiectasis","volume":"8","author":"Henkle","year":"2022","journal-title":"ERJ Open Res"},{"issue":"3","key":"10.1016\/j.rmed.2023.107217_bib77","first-page":"CD012579","article-title":"Oral versus inhaled antibiotics for bronchiectasis","volume":"3","author":"Spencer","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9","key":"10.1016\/j.rmed.2023.107217_bib78","first-page":"CD012590","article-title":"Head-to-head trials of antibiotics for bronchiectasis","volume":"9","author":"Kaehne","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.rmed.2023.107217_bib79","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1186\/s12889-019-7796-8","article-title":"The drivers of antibiotic use and misuse: the development and investigation of a theory driven community measure","volume":"19","author":"Byrne","year":"2019","journal-title":"BMC Publ. Health"},{"issue":"3","key":"10.1016\/j.rmed.2023.107217_bib80","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02327-20","article-title":"Pseudomonas aeruginosa susceptibility patterns and associated clinical outcomes in people with cystic fibrosis following approval of aztreonam lysine for inhalation","volume":"65","author":"Keating","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"13","key":"10.1016\/j.rmed.2023.107217_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127218","article-title":"The relationship between the structure and toxicity of aminoglycoside antibiotics","volume":"30","author":"Jospe-Kaufman","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.rmed.2023.107217_bib82","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3390\/ijms18051062","article-title":"Inhaled antibiotic therapy in chronic respiratory diseases","volume":"18","author":"Maselli","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.rmed.2023.107217_bib83","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/ja.2011.58","article-title":"Recent advances in materials for extended-release antibiotic delivery system","volume":"64","author":"Gao","year":"2011","journal-title":"J. Antibiot."},{"issue":"10","key":"10.1016\/j.rmed.2023.107217_bib84","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1164\/rccm.201605-1027OC","article-title":"Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis","volume":"195","author":"Chalmers","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.rmed.2023.107217_bib85","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/thoraxjnl-2012-201772","article-title":"Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis","volume":"68","author":"Andrejak","year":"2013","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.rmed.2023.107217_bib86","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1440-1843.2011.02076.x","article-title":"Increased risk of nontuberculous mycobacterial infection in asthmatic patients using long-term inhaled corticosteroid therapy","volume":"17","author":"Hojo","year":"2012","journal-title":"Respirology"},{"issue":"7","key":"10.1016\/j.rmed.2023.107217_bib87","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201205-0825OC","article-title":"Environment or host?: a case-control study of risk factors for Mycobacterium avium complex lung disease","volume":"186","author":"Dirac","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.rmed.2023.107217_bib88","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.chest.2017.04.167","article-title":"Pharmacotherapy for non-cystic fibrosis bronchiectasis. Results from an NTM info & research patient survey and the bronchiectasis and NTM research Registry","volume":"152","author":"Henkle","year":"2017","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.rmed.2023.107217_bib89","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1164\/rccm.202108-1889OC","article-title":"Characterization of eosinophilic bronchiectasis: a european multicohort study","volume":"205","author":"Shoemark","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"12","key":"10.1016\/j.rmed.2023.107217_bib90","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.rmed.2023.107217_bib91","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S2213-2600(14)70213-9","article-title":"The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial","volume":"2","author":"Rogers","year":"2014","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.rmed.2023.107217_bib92","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.rmed.2023.107217_bib93","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.chest.2021.02.019","article-title":"The association of long-term macrolide therapy and nontuberculous mycobacterial culture positivity in patients with bronchiectasis","volume":"160","author":"Metersky","year":"2021","journal-title":"Chest"},{"issue":"22","key":"10.1016\/j.rmed.2023.107217_bib94","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2023.107217_bib95","doi-asserted-by":"crossref","first-page":"293","DOI":"10.12688\/f1000research.17295.1","article-title":"Bronchiectasis insanity: Doing the same thing over and over again and expecting different results?","author":"Metersky","year":"2019","journal-title":"F1000 Faculty Rev."},{"issue":"Suppl 64","key":"10.1016\/j.rmed.2023.107217_bib96","first-page":"3332","article-title":"Heterogeneity of treatment response in bronchiectasis clinical trials","volume":"56","author":"Sibila","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2023.107217_bib97","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02058-2018","article-title":"Treatable traits down under international workshop participants, treatable traits: a new paradigm for 21st century management of chronic airway diseases: treatable traits down under international workshop report","volume":"53","author":"McDonald","year":"2019","journal-title":"Eur. Respir. J."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611123001051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611123001051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:16:04Z","timestamp":1762337764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611123001051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":97,"alternative-id":["S0954611123001051"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2023.107217","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards development of evidence to inform recommendations for the evaluation and management of bronchiectasis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2023.107217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107217"}}